Recent Changes

Friday, March 16

  1. page Medicinal Chemistry Dissertation edited Medicinal {Biological Evaluation Section of Thesis.pdf} Medicinal Chemistry Dissertation {The …
    Medicinal {Biological Evaluation Section of Thesis.pdf} Medicinal Chemistry Dissertation
    {The Drugs.pptx}
    {Jan Thesis talk Jan 18 Allan2.pptx}
    (view changes)
    6:00 am

Wednesday, March 14

  1. page Eli Lilly vs. Apotex edited Eli Lilly vs. Novopharm vs. Apotex The Drug ... as follows: {LLY31450.JPG} http://www.medhelp…
    Eli Lilly vs. Novopharm vs. Apotex
    The Drug
    ...
    as follows: {LLY31450.JPG} http://www.medhelp.org/tags/show/5067/nizatidine
    {Nizatidine.png}
    Nizatidine is absorbed into the bloodstream after taken orally with peak plasma concentration from 0.5 to 3 hours after administration. Food does not affect the rate of absorption. If any of the chemicals are taken at the same time, such as alcohol, caffeine, aluminum, magnesium, vitamin D, iron, zinc and fluoride, absorption will be reduced by approximately 10%. The bioavailability of the drug is 70.9% ± 6.4. Nizatidine has a binding affinity of 35% and a 0.8 to 1.5 L/kg volume of distribution.
    (view changes)
    10:51 am
  2. file LLY31450.JPG uploaded
    10:43 am
  3. file ZZZZ.htm uploaded
    10:42 am
  4. page Eli Lilly vs. Apotex edited ... Overdose generally results in lacrimation, salivation, emesis and diarrhea. It is also importa…
    ...
    Overdose generally results in lacrimation, salivation, emesis and diarrhea. It is also important to avoid taking any gastric pH modifiers and H2-receptor antagonists while taking this drug.
    The Conflict
    ...
    This patent (http://www.google.ca/patents?id=SF83AAAAEBAJ&printsec=abstract#v=onepage&q&f=false) was for
    Before this, a “supply agreement” was made between Novopharm and Apotex. This agreement stated that if either party had a license for a patented medicine, the unlicensed party was entitled to receive specified amounts of the medicine in question at a cost plus a four per cent royalty. In April 1993, Apotex filed a notice of compliance for the final dosage forms of nizatidine, claiming that no terms of the original patent would be invaded. Apotex also informed Novopharm and gave proof that this would be allowed based on the “supply agreement” filed with Novopharm.
    Eli Lilly then brought an application to inhibit Apotex from doing so all together or at least until the patent had expired in December 1997. Due to the struggle with this issue, in July 1993, Eli Lilly tried to terminate the license made with Novopharm, claiming that Novopharm had made a sublicense with Apotex, clearly breaching the contract. Novopharm fought back claiming no such thing was done with a sublicense or transfer of rights. The Federal Court denied Eli Lilly’s claim stating that there was no sublicense granted between Novopharm and Apotex, but also stated that if Apotex sold the drug in Canada, the original patent would be infringed.
    ...
    1. DrugBank: Nizatidine (DB00585). (n.d.). DrugBank. Retrieved March 14, 2012, from http://www.drugbank.ca/drugs/DB00585
    2. Eli Lilly vs. Novopharm vs. Apotex. (n.d.). Lexis Nexis. Retrieved March 3, 2012, from www.lexisnexis.com.uproxy.library.dc-uoit.ca/ca/legal/results/docview/docview.do?docLinkInd=true&risb=21_T14191915207&format=GNBFULL&sort=RELEVANCE&startDocNo=1&resultsUrlKey=29_T14191915210&cisb=22_T14191915209&treeMax=true&treeWidth=0&csi=281150&docNo=6
    ...
    2012, from http://www.google.ca/patents?id=SF83AAAAEBAJ&printsec=abstract#v=onepage&q&f=falsehttp://www.google.ca/patents?id=SF83AAAAEBAJ&printsec=abstract#v=onepage&q&f=falsehttp://www.google.ca/patents?id=SF83AAAAEBAJ&printsec=abstract#v=onepage&q&f=false
    (view changes)
    10:40 am
  5. page Eli Lilly vs. Apotex edited ... Eli Lilly failed to reveal evidence that the NOA was not justified or a good reason to termina…
    ...
    Eli Lilly failed to reveal evidence that the NOA was not justified or a good reason to terminate the license with Novopharm. Due to the other findings, it was deemed not necessary for the Court to grant declaratory relief on a limited judicial review proceeding of this type, the declaratory of relief was denied.
    References:
    1. http://www.lexisnexis.com.uproxy.library.dc-uoit.ca/ca/legal/results/docview/docview.do?docLinkInd=true&risb=21_T14191915207&format=GNBFULL&sort=RELEVANCE&startDocNo=1&resultsUrlKey=29_T14191915210&cisb=22_T14191915209&treeMax=true&treeWidth=0&csi=281150&docNo=6
    2.
    DrugBank: Nizatidine (DB00585). (n.d.). DrugBank. Retrieved March 14, 2012, from http://www.drugbank.ca/drugs/DB00585
    2. Eli Lilly vs. Novopharm vs. Apotex. (n.d.). Lexis Nexis. Retrieved March 3, 2012, from www.lexisnexis.com.uproxy.library.dc-uoit.ca/ca/legal/results/docview/docview.do?docLinkInd=true&risb=21_T14191915207&format=GNBFULL&sort=RELEVANCE&startDocNo=1&resultsUrlKey=29_T14191915210&cisb=22_T14191915209&treeMax=true&treeWidth=0&csi=281150&docNo=6

    3. Patent US4777260 - Synthesis of nizatidine intermediate - Google Patents. (n.d.). Google. Retrieved March 14, 2012, from http://www.google.ca/patents?id=SF83AAAAEBAJ&printsec=abstract#v=onepage&q&f=false
    (view changes)
    10:38 am
  6. page Eli Lilly vs. Apotex edited ... Novopharm issued a NOA July 1993 in support for a NOC and relied on the license between Eli Li…
    ...
    Novopharm issued a NOA July 1993 in support for a NOC and relied on the license between Eli Lilly and themselves that this would not infringe on the original patent. Eli Lilly brought this to the Federal Court requesting prohibition on this request due to the termination of the license between Eli Lilly and Novopharm. This would ensure that Novopharm could not manufacture or be in possession of the drug in any non-infringing way. Novopharms application was then turned down.
    The main issue of this case is determining whether there was actually a sublicense issued between Novopharm and Apotex in the use of nizatidine. If this was done, the NOA’s requested by both Novopharm and Apotex would not be justified, and Eli Lilly’s request for Novopharm to be prohibited from manufacturing the drug would be justified. The Court is asked to determine three things:
    1. whetherWhether the Federal
    ...
    or otherwise;
    2. whether

    Whether
    Novopharm's NOA
    ...
    NOA proposed;
    3. whether

    Whether
    the Federal
    Regardless of how it turns out with the sublicense, Apotex has still infringed the original patent by reformulating the final dosage form of Eli Lilly’s nizatidine.
    When someone receives a licence, they are considered the licensee. If this licensee grants certain rights regarding the original licence, the third party becomes the sublicensee and they have been granted a sublicense. In order for the agreement between Novopharm and Apotex to be considered a sublicense, Novopharm must have granted Apotex the rights to do something that would otherwise be forbidden by the original patent filed by Eli Lilly.
    ...
    Eli Lilly failed to reveal evidence that the NOA was not justified or a good reason to terminate the license with Novopharm. Due to the other findings, it was deemed not necessary for the Court to grant declaratory relief on a limited judicial review proceeding of this type, the declaratory of relief was denied.
    References:
    1. http://www.scbt.com/fr/datasheet-201125-fluoxetine-hcl.htmlhttp://www.lexisnexis.com.uproxy.library.dc-uoit.ca/ca/legal/results/docview/docview.do?docLinkInd=true&risb=21_T14191915207&format=GNBFULL&sort=RELEVANCE&startDocNo=1&resultsUrlKey=29_T14191915210&cisb=22_T14191915209&treeMax=true&treeWidth=0&csi=281150&docNo=6
    2.
    http://www.lexisnexis.com.uproxy.library.dc-uoit.ca/ca/legal/results/docview/docview.do?docLinkInd=true&risb=21_T14191915207&format=GNBFULL&sort=RELEVANCE&startDocNo=1&resultsUrlKey=29_T14191915210&cisb=22_T14191915209&treeMax=true&treeWidth=0&csi=281150&docNo=6
    http://www.drugbank.ca/drugs/DB00585
    3.
    http://www.drugbank.ca/drugs/DB00585
    4.
    http://www.google.ca/patents?id=SF83AAAAEBAJ&printsec=abstract#v=onepage&q&f=false
    (view changes)
    10:28 am
  7. page Eli Lilly vs. Apotex edited ... 3. http://www.drugbank.ca/drugs/DB00585 4. http://www.google.ca/patents?id=SF83AAAAEBAJ&…
    ...
    3.
    http://www.drugbank.ca/drugs/DB00585
    4. http://www.google.ca/patents?id=SF83AAAAEBAJ&printsec=abstract#v=onepage&q&f=false
    (view changes)
    10:25 am

More